Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 2/20 | 1.00 |
| ▸ | CDC25B | P30305 | 2/20 | 1.00 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.65 |
| ▸ | CES2 | O00748 | 7/20 | 0.56 |
| ▸ | CES1 | P23141 | 7/20 | 0.56 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | CDC25A | P30304 | 1/20 | 0.50 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | APAF1 | O14727 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7717344 | 0.85 | CDC25B (0.74) | PTPRCCDC25BPTPN1CES2CES1 | |
| SCHEMBL7717346 | 0.85 | CDC25B (0.74) | PTPRCCDC25BPTPN1CES2CES1 | |
| SCHEMBL29800450 | 0.85 | CDC25B (0.74) | PTPRCCDC25BPTPN1CES2CES1 | |
| SCHEMBL2511730 | 0.85 | CDC25B (0.74) | PTPRCCDC25BPTPN1CES2CES1 | |
| SCHEMBL4294847 | 0.83 | PTPRC (0.71) | PTPRCCDC25BPTPN1CES2CES1 | |
| SCHEMBL5595963 | 0.82 | PTPRC (0.70) | PTPRCCDC25BPTPN1CES2CES1 | |
| SCHEMBL5595620 | 0.82 | PTPRC (0.69) | PTPRCCDC25BPTPN1CES2CES1 | |
| SCHEMBL5595746 | 0.82 | PTPRC (0.69) | PTPRCCDC25BPTPN1CES2CES1 | |
| SCHEMBL14439360 | 0.80 | PTPRC (0.67) | PTPRCCDC25BPTPN1CES2CES1 | |
| SCHEMBL6052754 | 0.80 | PTPRC (0.67) | PTPRCCDC25BPTPN1CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7253207-B2 | Quinones as disease therapies | CELLGATE, INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-7253207-B2 | Quinones as disease therapies | CELLGATE, INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-7253207-B2 | Quinones as disease therapies | CELLGATE, INC. (US) | 2007-08-07 | — | — | US | disclosed |
| EP-0888326-B1 | NOVEL ORTHO-NAPHTHOQUINONE DERIVATIVES, NOVEL SYNTHESIS THEREFOR, AND THEIR USE IN THE INHIBITION OF NEOPLASTIC CELL GROWTH | WISCONSIN ALUMNI RES FOUND (US) | 2006-08-16 | — | — | EP | disclosed |
| US-6939896-B2 | Naphthalenedione derivatives; treating autoimmune diseases and organ graft rejection | ASTRAZENECA AB (SE) | 2005-09-06 | — | — | US | disclosed |
| EP-1259231-B1 | NAPHTHOQUINONE DERIVATIVES AS CD45 INHIBITORS | ASTRAZENECA AB (SE) | 2005-05-25 | — | — | EP | disclosed |
| US-20050010060-A1 | Novel quinones as disease therapies | SLIL BIOMEDICAL CORPORATION (US) | 2005-01-13 | — | — | US | disclosed |
| US-20030119897-A1 | Cd45 inhibitors | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | US | disclosed |
| EP-1259231-A2 | NAPHTHOQUINONE DERIVATIVES AS CD45 INHIBITORS | AstraZeneca AB (SE) | 2002-11-27 | — | — | EP | disclosed |
| WO-2001045681-A2 | NAPHTHOQUINONE DERIVATIVES AS CD45 INHIBITORS | ASTRAZENECA AB (SE) | 2001-06-28 | — | — | WO | disclosed |
| US-5977187-A | 4-substituted-1,2-naphthoquinones and their use in the inhibition of neoplastic cell growth | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1999-11-02 | — | — | US | disclosed |
| US-5883270-A | 4-substituted-1, 2-naphthoquinones and their use in the inhibition of neoplastic cell growth | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1999-03-16 | — | — | US | disclosed |
| EP-0888326-A2 | NOVEL ORTHO-NAPHTHOQUINONE DERIVATIVES, NOVEL SYNTHESIS THEREFOR, AND THEIR USE IN THE INHIBITION OF NEOPLASTIC CELL GROWTH | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997031936-A2 | NOVEL ORTHO-NAPHTHOQUINONE DERIVATIVES, NOVEL SYNTHESIS THEREFOR, AND THEIR USE IN THE INHIBITION OF NEOPLASTIC CELL GROWTH | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1997-09-04 | — | — | WO | disclosed |
| US-4882339-A | ANTIINFLAMMATORY, ANTIALLERGENS | CIBA-GEIGY CORPORATION (US) | 1989-11-21 | — | — | US | disclosed |
| EP-0298919-A2 | 4-amino-substituted 1,2-dihydroxynaphthalene derivatives | CIBA-GEIGY AG (CH) | 1989-01-11 | — | — | EP | disclosed |
| EP-0054230-B1 | MONOAZO DYESTUFFS AND USE AS IMAGE-FORMING DYESTUFFS IN COLOUR-PHOTOGRAPHIC REGISTRATION MATERIALS | Agfa-Gevaert AG (DE) | 1985-03-20 | — | — | EP | disclosed |
| EP-0054230-A2 | Monoazo dyestuffs and use as image-forming dyestuffs in colour-photographic registration materials | Agfa-Gevaert AG (DE) | 1982-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050010060-A1 | Novel quinones as disease therapies | NQO1, NDUFV2, SDHB | PTPRC 1827/4885CDC25B 1302/4885PTPN1 3247/4885 |
| US-20030119897-A1 | Cd45 inhibitors | PTPRC, CD2, HLA-C | PTPRC 1/4885CDC25B 187/4885PTPN1 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.